# A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

> **NCT01066390** · PHASE1 · COMPLETED · sponsor: **Bart Neyns** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** TriMix-DC

## Key facts

- **NCT ID:** NCT01066390
- **Lead sponsor:** Bart Neyns
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-11
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2014-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066390, "A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01066390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*